Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 24;94(20):7278-7285.
doi: 10.1021/acs.analchem.2c00554. Epub 2022 May 9.

Aptamer Sandwich Lateral Flow Assay (AptaFlow) for Antibody-Free SARS-CoV-2 Detection

Affiliations

Aptamer Sandwich Lateral Flow Assay (AptaFlow) for Antibody-Free SARS-CoV-2 Detection

Lucy F Yang et al. Anal Chem. .

Abstract

The COVID-19 pandemic is among the greatest health and socioeconomic crises in recent history. Although COVID-19 vaccines are being distributed, there remains a need for rapid testing to limit viral spread from infected individuals. We previously identified the SARS-CoV-2 spike protein N-terminal domain (NTD) binding DNA aptamer 1 (SNAP1) for detection of SARS-CoV-2 virus by aptamer-antibody sandwich enzyme-linked immunoassay (ELISA) and lateral flow assay (LFA). In this work, we identify a new aptamer that also binds at the NTD, named SARS-CoV-2 spike protein NTD-binding DNA aptamer 4 (SNAP4). SNAP4 binds with high affinity (<30 nM) for the SARS-CoV-2 spike protein, a 2-fold improvement over SNAP1. Furthermore, we utilized both SNAP1 and SNAP4 in an aptamer sandwich LFA (AptaFlow), which detected SARS-CoV-2 UV-inactivated virus at concentrations as low as 106 copies/mL. AptaFlow costs <$1 per test to produce, provides results in <1 h, and detects SARS-CoV-2 at concentrations that indicate higher viral loads and a high probability of contagious transmission. AptaFlow is a potential approach for a low-cost, convenient antigen test to aid the control of the COVID-19 pandemic.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A naïve aptamer library is enriched for S-2P binders by cell SELEX then protein SELEX. In cell SELEX, HEK293_S-2P cells are used for positive selection and HEK293 cells are used for negative selection. In protein SELEX, S-2P recombinant protein is used for positive selection and bovine serum albumin (BSA) is used for negative selection. Aptamer pools are evaluated for binding to targets and sequenced.
Figure 2.
Figure 2.
A) Cy5-labeled SNAP4 at various concentrations was incubated with HEK293_S-2P cells to generate a binding curve. The graph shows the total (blue) and non-specific (gray) binding of aptamer based on a one-site binding model (dashed lines). KD was determined by non-linear regression (1 biological replicate.) B-C) Biotinylated aptamer was loaded on SA biosensors and associated with protein. The gray lines indicate the switch from analyte association to dissociation. Kon values (mean±s.d., n= 4–6) were determined from a global fit (dark gray line) of the kinetic data at various concentrations of proteins for the indicated binding model. B) SNAP4 aptamer binding to S-2P protein fitted to a 1:1 model for association only. C) SNAP4 aptamer (left) or SNAP4.74 aptamer (right) binding to S1 protein with 1:2 model fit (top) or NTD protein with 1:1 model fit (bottom).
Figure 3.
Figure 3.
A) Step-by-step process for AptaFlow. (i) incubating reagents with SARS-CoV-2 sample. (ii) dipping of the test strip into the sample. (iii) washing to reduce non-specific signals. (iv) enhancing signal to increase sensitivity. B) Limit of detection of LFA system with UV-inactivated virus (UV) at various concentrations (copies/mL) and heat-inactivated (HI) virus (negative control). Bars indicate mean. Brackets indicate 95% CI. Statistical significance was determined by one-way ANOVA with Dunnett correction. * indicates p < 0.05 and **** indicates p < 0.0001 when compared to HI 1 × 107 copies/mL; n = 3–4 per experimental group. A representative image is shown.

Similar articles

Cited by

References

    1. Wouters OJ; Shadlen KC; Salcher-Konrad M; Pollard AJ; Larson HJ; Teerawattananon Y; Jit M Challenges in Ensuring Global Access to COVID-19 Vaccines: Production, Affordability, Allocation, and Deployment. The Lancet 2021, 397 (10278), 1023–1034. 10.1016/S0140-6736(21)00306-8. - DOI - PMC - PubMed
    1. Peeling RW; Olliaro PL; Boeras DI; Fongwen N Scaling up COVID-19 Rapid Antigen Tests: Promises and Challenges. Lancet Infect. Dis. 2021, 21 (9), e290–e295. 10.1016/S1473-3099(21)00048-7. - DOI - PMC - PubMed
    1. Larremore DB; Wilder B; Lester E; Shehata S; Burke JM; Hay JA; Milind T; Mina MJ; Parker R Test Sensitivity Is Secondary to Frequency and Turnaround Time for COVID-19 Surveillance. medRxiv 2020, 2020.06.22.20136309. 10.1101/2020.06.22.20136309. - DOI - PMC - PubMed
    1. Mina MJ; Parker R; Larremore DB Rethinking Covid-19 Test Sensitivity — A Strategy for Containment. N. Engl. J. Med. 2020, 383 (22), e120. 10.1056/NEJMp2025631. - DOI - PubMed
    1. Nimjee SM; Rusconi CP; Sullenger BA Aptamers: An Emerging Class of Therapeutics. Annu. Rev. Med. 2005, 56 (1), 555–583. 10.1146/annurev.med.56.062904.144915. - DOI - PubMed

Publication types